Last reviewed · How we verify
AZD6234 in combination with AZD9550
AZD6234 is a PI3K inhibitor, and AZD9550 is a CDK9 inhibitor, which together target cancer cell growth and survival.
AZD6234 is a PI3K inhibitor, and AZD9550 is a CDK9 inhibitor, which together target cancer cell growth and survival. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | AZD6234 in combination with AZD9550 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K inhibitor and CDK9 inhibitor |
| Target | PI3K and CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD6234 works by inhibiting the PI3K pathway, which is involved in cell growth and survival. AZD9550 targets CDK9, an enzyme that plays a role in the transcription of genes involved in cancer cell proliferation. By combining these two mechanisms, AZD6234 and AZD9550 aim to inhibit cancer cell growth and survival.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (PHASE2)
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (PHASE2)
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6234 in combination with AZD9550 CI brief — competitive landscape report
- AZD6234 in combination with AZD9550 updates RSS · CI watch RSS
- AstraZeneca portfolio CI